Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

Similar articles for PubMed (Select 24359174)

1.

Plasma oxytocin changes and anti-obsessive response during serotonin reuptake inhibitor treatment: a placebo controlled study.

Humble MB, Uvnäs-Moberg K, Engström I, Bejerot S.

BMC Psychiatry. 2013 Dec 23;13:344. doi: 10.1186/1471-244X-13-344.

2.

Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial.

Denys D, Van Nieuwerburgh F, Deforce D, Westenberg HG.

J Clin Psychiatry. 2007 May;68(5):747-53.

PMID:
17503984
3.

A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder.

Denys D, van Megen HJ, van der Wee N, Westenberg HG.

J Clin Psychiatry. 2004 Jan;65(1):37-43.

PMID:
14744166
4.
5.
6.

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.

JAMA Psychiatry. 2013 Nov;70(11):1190-9. doi: 10.1001/jamapsychiatry.2013.1932.

7.

Issues in the pharmacological treatment of obsessive-compulsive disorder.

Math SB, Janardhan Reddy YC.

Int J Clin Pract. 2007 Jul;61(7):1188-97. Epub 2007 May 18. Review.

PMID:
17511795
8.

Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.

J Clin Psychiatry. 2004 Apr;65(4):565-8.

PMID:
15119922
9.
10.

A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.

Denys D, van der Wee N, van Megen HJ, Westenberg HG.

J Clin Psychopharmacol. 2003 Dec;23(6):568-75.

PMID:
14624187
11.

Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study.

Kordon A, Wahl K, Koch N, Zurowski B, Anlauf M, Vielhaber K, Kahl KG, Broocks A, Voderholzer U, Hohagen F.

J Clin Psychopharmacol. 2008 Oct;28(5):550-4. doi: 10.1097/JCP.0b013e318185e735.

PMID:
18794652
12.

Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.

Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V.

J Affect Disord. 2010 Feb;121(1-2):175-9. doi: 10.1016/j.jad.2009.06.010. Epub 2009 Jul 3.

13.

Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.

Humble M, Bejerot S, Bergqvist PB, Bengtsson F.

Biol Psychiatry. 2001 Feb 15;49(4):360-8.

PMID:
11239907
14.

Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Muscatello MR, Bruno A, Pandolfo G, Micò U, Scimeca G, Romeo VM, Santoro V, Settineri S, Spina E, Zoccali RA.

J Clin Psychopharmacol. 2011 Apr;31(2):174-9. doi: 10.1097/JCP.0b013e31820e3db6.

PMID:
21346614
15.

Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.

Storch EA, Goddard AW, Grant JE, De Nadai AS, Goodman WK, Mutch PJ, Medlock C, Odlaug B, McDougle CJ, Murphy TK.

J Clin Psychiatry. 2013 Jun;74(6):e527-32. doi: 10.4088/JCP.12m08278.

PMID:
23842022
16.

Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder.

Koran LM, Aboujaoude E, Bullock KD, Franz B, Gamel N, Elliott M.

J Clin Psychiatry. 2005 Mar;66(3):353-9.

PMID:
15766302
17.

Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.

Koran LM, Aboujaoude E, Gamel NN.

J Clin Psychiatry. 2009 Nov;70(11):1530-5. doi: 10.4088/JCP.08m04605. Epub 2009 Jun 30.

PMID:
19573497
18.

A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.

McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH.

Arch Gen Psychiatry. 2000 Aug;57(8):794-801.

PMID:
10920469
19.

Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Aboujaoude E, Barry JJ, Gamel N.

J Clin Psychopharmacol. 2009 Feb;29(1):51-5. doi: 10.1097/JCP.0b013e318192e9a4.

PMID:
19142108
20.

Clinical predictors of drug nonresponse in obsessive-compulsive disorder.

Shetti CN, Reddy YC, Kandavel T, Kashyap K, Singisetti S, Hiremath AS, Siddequehusen MU, Raghunandanan S.

J Clin Psychiatry. 2005 Dec;66(12):1517-23.

PMID:
16401151
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk